RÉSUMÉ
Eosinophilic dermatosis of hematologic malignancy (EDHM) is a cutaneous manifestation seen in patients with hematoproliferative and lymphoproliferative disorders, most commonly chronic lymphocytic leukemia. This systematic review aimed to summarize the therapeutic interventions of EDHM. A comprehensive search yielded 71 studies, predominantly case reports and series. The most frequently reported modalities were systemic and topical corticosteroids, as well as treatment of the underlying malignancy. Responses to these treatments varied. Targeted therapies, including dupilumab and omalizumab, showed promise, as did other modalities such as montelukast, dapsone, doxycycline, and phototherapy. Higher-quality studies should be conducted to facilitate higher-quality management recommendations for EDHM.
Sujet(s)
Association amoxicilline-clavulanate de potassium/usage thérapeutique , Antibactériens/usage thérapeutique , Érythème/traitement médicamenteux , Kératose/traitement médicamenteux , Adulte , Érythème/anatomopathologie , Femelle , Humains , Kératose/anatomopathologie , Mâle , Adulte d'âge moyenRÉSUMÉ
Tocilizumab is a humanized monoclonal antibody to the interleukin-6 (IL-6) receptor which was first approved for use in refractory rheumatoid arthritis almost a decade ago. Since then, its use has expanded to a number of rheumatological and inflammatory conditions. In dermatology, off-label use of tocilizumab has been reported to be efficacious in morphoea, systemic sclerosis, psoriasis, atopic dermatitis, vitiligo, graft-versus-host disease, pyoderma gangrenosum, Behcet's disease, Schnitzler's syndrome, sarcoidosis, and cutaneous adverse reactions. That being said, the evidence demonstrating tocilizumab's efficacy in dermatology is predominantly low-level case-based evidence, and one must consider the potential for publication bias. In this review we will discuss the reported clinical applications of tocilizumab in dermatology, mechanisms of action, and the range of associated adverse effects (both cutaneous and non-cutaneous) that can occur. Additionally, we will discuss the role of tocilizumab in the management of COVID-19.
Sujet(s)
Traitements médicamenteux de la COVID-19 , Dermatologie , Anticorps monoclonaux humanisés , Humains , SARS-CoV-2RÉSUMÉ
We report the case of a 20-year-old woman with intracranial IgG4-related disease, initially misdiagnosed as a meningioma on biopsy and treated with radiosurgery as it was in an eloquent location and not resectable. Her intracranial IgG4 disease had a near-complete response to radiosurgery and is still controlled six years later, so this case represents what we believe to be the first reported use of radiotherapy in the treatment of intracranial IgG4-related disease.